LOGIN  |  REGISTER
Recursion

Ocumetics Technology (TSX.V: OTC) Stock Quote

Last Trade: C$0.35 0.03 9.38
Volume: 39,000
5-Day Change: 12.90%
YTD Change: 2.94%
Market Cap: C$41.920M

Latest News From Ocumetics Technology

Calgary, Alberta – TheNewswire - August 29, 2024 - Ocumetics Technology Corp. (“ Ocumetics ”) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is pleased to announce the successful fabrication of an intraocular lens (IOL) that is designed to respond to muscle activity that controls the curvature of the natural lens in the human eye. This achievement puts Ocumetics one step closer to the... Read More
Calgary, Alberta – TheNewswire - August 8, 2024 - Ocumetics Technology Corp. (“ Ocumetics ”) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a pioneer in vision enhancement technology, is excited to announce the successful development of a new injector system specifically designed for implantation of the Ocumetics Accommodative Intraocular lens (the “Ocumetics Lens”). This achievement marks a significant milestone in Ocumetics’... Read More
Calgary, Alberta – TheNewswire - July 22, 2024 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in vision enhancement technology, is pleased to announce that its intraocular lenses are now being manufactured for the upcoming first-in-human study in the Dominican Republic. “We are thrilled to collaborate with Bioana, leveraging their medical device expertise... Read More
Calgary, Alberta – June 21, 2024. - Th eNewswire - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the second tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024 and May 23, 2024. The Corporation has issued secured convertible debentures having an aggregate face value principal amount... Read More
Calgary, Alberta – May 24, 2024 - TheNewswire. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024. The Corporation has issued secured convertible debentures having an aggregate face value principal amount of $3,000,000 (the “... Read More
Calgary, Alberta – TheNewswire - May 15, 2024. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the “ Principal ”). The debentures will be subject to an original issue discount of 6%, resulting in... Read More
Ocumetics Technology Corp. (“Ocumetics”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research. Martin Gagel of Market Radius Research and CEO Dean Burns will be discussing Ocumetics’ revolutionary accommodating intraocular lens, the successful completion of animal studies and the upcoming First in Human study. The webinar... Read More
Calgary, Alberta – TheNewswire - January 17, 2024 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed the private placement previously announced by the Corporation on November 15, 2023 and December 21, 2023. The Corporation issued an aggregate of 1,301,875 units (“ Units ”) pursuant to the private placement, at a price of $0.32, for total... Read More
Calgary, Alberta – TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation’s non-brokered private placement announced on November 15, 2023. The new closing deadline for the private placement is January 15, 2024. The Corporation is proposing... Read More
Calgary, Alberta - TheNewswire - December 15, 2023. - Ocumetics Technology Corp. (“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) , a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic. Dean Burns, CEO of Ocumetics and 27-year Alcon... Read More
Calgary, Alberta – TheNewswire - December 7, 2023 - Ocumetics Technology Corp. (“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in the field of ophthalmic innovation, proudly confirms the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic. The biocompatibility of the Ocumetics accommodating... Read More
Calgary, Alberta – TheNewswire - November 15, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it proposes to complete a non-brokered private placement of up to 3,125,000 units of the Corporation (“ Units ”) at a price of $0.32 per Unit for gross proceeds of up to $1,000,000. There will be no minimum subscription level for this offering. Each Unit will... Read More
Calgary, Alberta – September 18, 2023. Ocum etics Technology Corp. (“ Ocumetics ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in in the field of ophthalmic innovation, proudly confirms a remarkable achievement in the optimization of its vision correction technology - the Ocumetics Accommodating Lens. Through rigorous research and development efforts over the past two years, Ocumetics has modified its lens design five... Read More
Calgary, Alberta – TheNewswire - September 1, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in advanced eye care solutions, is pleased to announce the appointment of Dr. Doyle Stulting and Dr. Bart McRoberts to its Board of Directors. With their unparalleled expertise in ophthalmology and vision research, Drs. Stulting and McRoberts bring a wealth of... Read More
Calgary, Alberta – TheNewswire - August 15, 2023. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed the private placement previously announced by the Corporation on June 22, 2023. The Corporation issued an aggregate of 3,333,333 units (“ Units ”) pursuant to the private placement, at a price of $0.30, for total gross proceeds of $1,000,000.... Read More
Calgary, Alberta – TheNewswire - July 25, 2023. Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed the first tranche of the private placement previously announced by the Corporation on June 22, 2023. The Corporation has issued an aggregate of 1,880,868 units (“ Units ”) at a price of $0.30 per unit for aggregate gross proceeds of $564,260.40.... Read More
Calgary, Alberta – TheNewswire - June 22, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it proposes to complete a non-brokered private placement of up to 3,333,333 units of the Corporation (“ Units ”) at a price of $0.30 per Unit for gross proceeds of up to $1,000,000. There will be no minimum subscription level for this offering. Each Unit will... Read More
Calgary, Alberta – TheNewswire - June 20 , 2023 - Ocumetics Technology Corp. (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) (“ Ocumetics ” or the “ Company ”) is pleased to announce that the Company has reached a major milestone with the start of biocompatibility and animal studies for its updated lens design. As a result of extensive product testing and preliminary animal studies over the past 18 months, the Ocumetics research and... Read More
Dean Burns, a 27-year Alcon Vision veteran, will lead Ocumetics through the clinical trial and commercialization process Calgary, Alberta – TheNews wire - June 12 , 2023 - Ocumetics Technology Corp. (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) (“ Ocumetics ” or the “ Corporation ”) is pleased to announce that it has appointed Mr. Dean Burns as Ocumetics’ President and CEO. Mr. Burns will also join the Ocumetics board of directors. Mr.... Read More
Calgary, Alberta – TheNewswire - April 24, 2023. Ocumetics Technology Corp. (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) (the “ Corporation ” or “ Ocumetics ”) announces that Dr. Mark Lee has tendered his resignation as the Corporation’s President and Chief Executive Officer to take effect June 30, 2023. Dr. Lee will continue as the Corporation’s President and Chief Executive Officer until June 30, 2023 as the Corporation seeks to hire... Read More
Calgary, Alberta – TheNewswire - April 19, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Company ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that its research and development team has successfully completed design lockdown for the Ocumetics accommodating lens that will move into the next stage of testing. “This announcement represents the completion of thousands of hours of design work and bench... Read More
Calgary, AB - TheNewswire - February 13, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Company ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce the successful completion of its latest animal studies. “The purpose of these studies was to test our latest design,” said Dr. Garth Webb, Ocumetics’ Founder and Chief Scientific Officer. “The lens design met and exceeded our expectations. It is exciting to... Read More
Calgary, Alberta – TheNewswire – February 1, 2023 - Ocumetics Technology Corp. (“ Ocumetics ” or the “ Corporation ”) ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) announces that it has completed a private placement of 1,493,574 units of the Corporation (“ Units ”) at a price of $0.45 per Unit for gross proceeds of $672,108.15. Each Unit consists of one common share in the share capital of the Corporation (“ Common Share ”) and... Read More
Astria Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB